Ricerc@Sapienza

Pancreatic surgery is still the only curative treatment for the majority of pancreatic neoplasms.
Pancreatic carcinoma represents the fourth-leading cause of cancer-related death in the United States with 46,420 estimated new cases for 2014 and 35,590 deaths. In Europe, 103,773 new cases were estimated in 2012, and 8.15 deaths/100,000 in men and 5.62/100,000 in women. Adenocarcinoma of the pancreas is the most aggressive pancreatic neoplasm, with approximately 80 % of patients inoperable at the time of the diagnosis for locally advanced or metastatic disease. Pancreatic Neuroendocrine tumors (pNETs) represent about 7% of all NETs, 8.7% of gastroenteropancreatic NETs (GEP-NETs) and 1% to 2% of all pancreatic neoplasms. pNETs are further divided into functional and non-functional tumors, depending their secretive activity. Pancreatic robotic enucleation is a safe and feasible procedure with lower intraoperative blood loss, better perioperative outcomes, mortality rates less than 1% and shorter hospital stays compared with open surgery. The current literature is still lacking studies matching robotics, laparoscopic and open surgery. In our experience robotic enucleation is a safe procedure that allows sparing more parenchyma, reducing the risk of develop iatrogenic diabetes. Moreover, patients have a short hospital stay with a precocious return to every-day activities.